Haemonetics Corporation HAE
At closeNov 6, 2026, 5:31 PM EST
After hours · Nov 6, 5:31 PM ET
- YTD
- +49.63%
- 1 year
- +78.71%
- Market cap
- 5.46B
- Revenue (ttm)
- 1.38B
- Profit margin
- 7.52%
- EPS (ttm)
- 2.26
- Shares out
- 45.50M
- P/E ratio
- 53.07
- Forward P/E
- 20.77
- YTD return
- +49.63%
- 1-year return
- +78.71%
- Volume
- 834.68K
- Avg volume
- 712.69K
- Open
- 121.16
- Previous close
- 124.11
- Day's range
- 116.79 – 123.75
- 52-week range
- 52.24 – 127.42
- Analysts
- Buy
- Price target
- 124.50 (+3.8%)
- Earnings date
- Feb 4, 2027
5D -0.55 (-0.46%)
Key statistics
- Enterprise value
- 6.51B
- PEG ratio
- 1.97
- Price / sales
- 3.95
- Price / book
- 6.08
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 9.30%
- Free cash flow
- 272.70M
- Total cash
- 260.71M
- Total debt
- 1.12B
- Return on equity
- 11.89%
- Short % of float
- 8.82%
- 50-day average
- 111.17
- 200-day average
- 79.66
Analyst view
Consensus: buy
- Target (low)
- 86.00
- Target (mean)
- 124.50
- Target (high)
- 142.00
- Strong buy4
- Buy5
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 4, 2027
Expected Feb 4, 2027. Consensus EPS estimate 1.36.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 4, 2027 | Dec 26, 2026 | 1.36 | — | — | — |
| Nov 5, 2026 | Sep 26, 2026 | 1.29 | 1.35 | +0.06 | +4.65% |
| Aug 6, 2026 | Jun 27, 2026 | 1.08 | 1.14 | +0.06 | +5.56% |
| May 7, 2026 | Mar 28, 2026 | 1.28 | 1.29 | +0.01 | +0.78% |
| Feb 5, 2026 | Dec 27, 2025 | 1.27 | 1.31 | +0.04 | +3.15% |
| Nov 6, 2025 | Sep 27, 2025 | 1.12 | 1.27 | +0.15 | +13.39% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 6, 2026 | Barrington Research | main | Outperform | Outperform |
| Nov 5, 2026 | BTIG | main | Buy | Buy |
| Oct 9, 2026 | Barrington Research | main | Outperform | Outperform |
| Oct 9, 2026 | Mizuho | main | Outperform | Outperform |
| Oct 8, 2026 | BTIG | main | Buy | Buy |
| Sep 17, 2026 | Citigroup | up | Neutral | Buy |
About Haemonetics Corporation
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools. The company also offers treatment in electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery; SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures; and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio, as well as fiber optic sensor solutions used in medical devices and other critical industrial applications. In addition, it provides hospital products comprising TEG 6s system, smallest cartridge-based viscoelastic analyzer that provides a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, the company offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries;vascular closure products comprise VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen; and transfusion management solutions. It sells its products through direct sales force and independent distributors. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- haemonetics.com
News
Haemonetics Q2 Earnings Call Highlights 
Citigroup Maintains Buy on Haemonetics, Raises Price Target to $149 
Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $145 
BTIG Maintains Buy on Haemonetics, Raises Price Target to $142 
Haemonetics Q2 2027 Earnings Call Transcript 
Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates - Haemonetics Raises FY2027 Sales Guidance from $1.401B-$1.441B to $1.441B-$1.481B vs $1.418B Est
- Haemonetics Q2 Adj. EPS $1.35 Beats $1.29 Estimate, Sales $357.759M Beat $345.003M Estimate
Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website 
BioCryst: Solid Q3 Earnings, But Long-Acting HAE Data Due 2027 The Key Catalyst
Your note
Sign in to keep a note on HAE — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABERNATHY ROBERT E | Director | Stock Award(Grant) | Jul 23, 2026 | 27,519 |
| BASIL MICHELLE L | General Counsel | Stock Award(Grant) | May 14, 2026 | 68,829 |
| DARECCA JAMES | Chief Financial Officer | Stock Award(Grant) | May 14, 2026 | 54,444 |
| DOCKENDORFF CHARLES J | Director | Stock Award(Grant) | Jul 23, 2025 | 25,041 |
| GALVIN ROY | Officer | Stock Award(Grant) | May 14, 2026 | 39,882 |
| KROLL MARK W | Director | Stock Award(Grant) | Jul 23, 2026 | 27,295 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.99% | 5,909,258 | 709.11M | Jun 29, 2026 |
| Neuberger Berman Group, LLC | 9.19% | 4,179,443 | 501.53M | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.60% | 2,546,394 | 305.57M | Jun 29, 2026 |
| AQR Capital Management, LLC | 4.98% | 2,266,489 | 271.98M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.53% | 2,059,578 | 247.15M | Jun 29, 2026 |
| Ariel Investments, LLC | 4.53% | 2,060,966 | 247.32M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Mid-Cap ETF | 3.56% | 1,621,301 | 194.56M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.17% | 1,441,654 | 173.00M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.62% | 1,194,166 | 143.30M | Sep 29, 2026 |
| NEUBERGER BERMAN EQUITY FUNDS-Neuberger Genesis Fund | 2.59% | 1,179,168 | 141.50M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.29% | 1,041,356 | 124.96M | Jun 29, 2026 |
| Touchstone Strategic TRT-Touchstone Strategic TRT-Touchstone Small Com | 1.35% | 614,824 | 73.78M | Jun 29, 2026 |